INNOVADERM CRO IS NOW INDERO.
READ THE ANNOUNCEMENT
Talk to us

Palmoplantar Pustulosis (PPP) Case Study

Indero

Indero

Team of Experts

Author picture

Outcomes

Innovaderm successfully managed this PPP study and this resulted in:

  • Enrollment completed 3 weeks ahead of schedule; Successful study and satisfied sponsor

Study Characteristics

  • Study Phase: II
  • Patient Population: Palmoplantar pustulosis
  • IP Route of Administration: Systemic
  • Sites Distribution: 17 sites in 2 countries (Canada, Germany)
  • Study Complexities: Presence of active lesions required, high PPPASI and PPPGA

Study Challenges and Solutions

Challenge 1: Site Selection

Identification of sites due to limited pool of patients with rare diseases

Solutions

  • Early activation of sites in Germany
  • Timely assessment of potential challenges with site selection
  • Implementation of in-house central campaign

Outcome

  • Enrollment completed 3 weeks ahead of schedule

Challenge 2: Recruitment

  • Participant apprehension regarding biopsy consent
  • Hassle of transporting IP between site and patient’s home
  • Short treatment period deterred interest in participation

Solutions

  • Strong presence of on-site staff to address questions or concerns related to participation

Outcome

  • Successful study and satisfied sponsor (+40%)

Key Success Factors & Strategies

  • Activation of sites in Germany to bolster recruitment
  • Effective in-house central campaigns
  • Project team’s tremendous engagement with sites to drive recruitment
SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.
Talk to us

Jeff Smith

Chef de la direction

Jeff Smith, Chef de la direction d’Indero Recherches, apporte prĂšs de 30 ans d’expĂ©rience dans l’industrie pharmaceutique et CRO, s’Ă©tant distinguĂ© par son leadership exceptionnel, sa vision stratĂ©gique et son innovation. L’expertise de Jeff couvre des opĂ©rations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matiĂšre de crĂ©ation de valeur, de gestion des partenaires et d’opĂ©rations CRO ont toujours contribuĂ© au succĂšs dans ses fonctions prĂ©cĂ©dentes. Sous la direction de Jeff, Indero continue d’étendre ses capacitĂ©s, faisant progresser les connaissances mĂ©dicales et les nouvelles thĂ©rapies en dermatologie et en rhumatologie.

Is Now

We are excited to announce that Innovaderm is rebranding our CRO division as Indero (in-dAIR-oh). This rebranding reflects our ongoing commitment to innovation and our expansion into the field of rheumatology, a therapeutic area closely linked to dermatology. As a dual-focus CRO specializing in both dermatology and rheumatology, this strategic decision marks a significant milestone for our organization, and we are eager to embark on this new chapter with our valued partners and clients. Additionally, our Clinical Research Unit (CRU) will keep the name Innovaderm and will continue to conduct dermatology studies.